drugset
Drugs / MC-1-50
last change May 2026 re-read 3 minutes ago

MC-1-50

Cell therapy targets CD19

Developed for
acute lymphoblastic leukemia · neoplasm of mature B-cells · non-Hodgkin lymphoma · systemic lupus erythematosus
Investigated by
Chongqing Precision Biotech Co., Ltd · Peking University Cancer Hospital & Institute · Ruijin Hospital · Second Affiliated Hospital, School of Medicine, Zhejiang University

Trials 3

today NCT06892145 · Ph 1 NCT06641024 · Ph 1 NCT06180174 · Ph 1
2024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06892145 Jun 2025 → May 2026 overdue systemic lupus erythematosus Chongqing Precision Biotech Co., Ltd Recruiting No outcome recorded
Phase 1 NCT06641024 Nov 2024 → Nov 2027 expected acute lymphoblastic leukemia Chongqing Precision Biotech Co., Ltd Not yet recruiting No outcome recorded
Phase 1 NCT06180174 Dec 2023 → Dec 2025 overdue neoplasm of mature B-cells, non-Hodgkin lymphoma Chongqing Precision Biotech Co., Ltd Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as MC-1-50 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06641024 ↗
2

NCT06892145 ↗

NCT06180174 ↗
Modality Cell therapy “CD19-targeting CAR-T” NCT06180174 ↗
Route Intravenous “administered intravenously” NCT06180174 ↗
Target CD19 “specific CD19-targeting CAR-T” NCT06180174 ↗